retatrutide weight loss chart Phase 3 obesity trial is out. Here is a comparison: Average loss: Wegovy: 14.9% Zepbound: 22.5% Retatrutide: 28.3% Sleeve gastrectomy: Gastric bypass Retatrutide Weight Loss Tracker, Reta

doi: 10.1210/jc.2004-0039 36 SakaiKDErcoleAJMurphyLJClemmonsDR

Read guide Getting started Step-by-step from intake to dose escalation

Administration of Exendin-4 but not CCK alters lick responses and trial initiation to sucrose and intralipid during brief-access tests

Quick Reference: Standard Protocol Self-reported starting doses begin around 0.25 mg 3x weekly for 2-4 weeks to assess tolerance, before increasing to 0.5 mg 3x weekly

This provides members with options to achieve lasting results with or without GLP-1s, and in turn enables employers and health plans to get the most out of their medication investment